Scottish-Korean link-up for diabetes drug development

Published: 2-Jun-2006

Glasgow-based Scottish Biomedical and South Korean pharmaceutical company Chong Kun Dang (CKD) have signed a research collaboration agreement focusing on the development of new drugs to treat diabetes.


Glasgow-based Scottish Biomedical and South Korean pharmaceutical company Chong Kun Dang (CKD) have signed a research collaboration agreement focusing on the development of new drugs to treat diabetes.

The deal is being funded through the Korean Health Industry Development Institute's (KHIDI) Inter-national Collaborative Research Programme for Drug Development (ICRPDD) and has been made possible by support from Scottish Development International. Scottish Biomedical will provide biological and medicinal chemistry expertise.

"This deal was won against international competition because CKD was convinced that Scottish scientists and technologies are at the forefront in the fight against human disease," said Stephen Hammond, ceo of Scottish Biomedical.

"I am delighted to be working with Scottish Biomedical on this important project. [It is] my hope that Scottish Biomedical and Chong Kun Dang can seize this valuable opportunity to deepen mutual understanding of each nation's technology and establishing strategic win-win partnership in various ways through this project," said . CKD president Dr Jung-Woo Kim.

Scottish Development International has been building relationships with South Korea's life sciences communities since the signing of a BioAlliance agreement in 2002. This is the third multi-million pound research partnerships signed through the link up over the past year.

You may also like